EUVIMEDEUVIMED entdecken
Evaluationsstudie

Analysis of appropriateness and safety when discharging patients on triple-antithrombotic therapies

Taylor Robichaux, Kristyn Edwards, Ashley Carter, Andrea Washington, Shelby Brooks

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae068 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Taylor Robichaux und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ochsner LSU Health Shreveport-Academic Medical Center, Shreveport, LA, USA. Hauptthemen laut MEDLINE: Patient Discharge, Heart Valve Diseases, Fibrinolytic Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To analyze the appropriateness of triple-antithrombotic therapy based on the 2020 American College of Cardiology (ACC) consensus statement while evaluating safety outcomes for patients with respect to adverse events.

Methods

A single-center, retrospective chart review was conducted using electronic medical records from December 18, 2020, to August 31, 2022. The primary endpoint was the rate of appropriateness for triple-antithrombotic therapy in patients discharged from Ochsner LSU Health Shreveport. Appropriateness was a composite endpoint extrapolated from the 2020 ACC consensus statement. For therapy to be defined as appropriate, patients had to have had the correct therapy indication, medications, dosing, and 30-day duration. Secondary safety endpoints included the percentage of patients rehospitalized at 14 and 30 days, the rate of major bleeding events, and the percentage of patients on gastrointestinal prophylaxis while on triple-antithrombotic therapy.

Results

A total of 93 patients were included in the study, of whom 31 (33%) received appropriate triple-antithrombotic therapy. Prolonged duration of triple-antithrombotic therapy was the most common reason that therapy did not meet the primary endpoint. The readmission rate due to bleeding was 2.2% at 14 days and 6.5% at 30 days. Within 30 days of initiation of triple therapy, 4.3% of patients endured major bleeding as defined by the International Society on Thrombosis and Hemostasis and 2 patients died.

Conclusion

In this single-center study, triple-antithrombotic therapy appropriately adhered to the 2020 ACC consensus statement for one-third of patients discharged on this therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient DischargeHeart Valve DiseasesFibrinolytic AgentsPractice Patterns, Physicians'Drug Therapy, CombinationRetrospective StudiesElectronic Health RecordsFemaleMiddle AgedAgedCardiologyConsensusMedication AdherencePatient ReadmissionHemorrhageHumans

Stichwörter der Autor:innen

anticoagulantsanticoagulationantiplateletsantithrombotic agentsdual antiplatelet therapytriple therapy

Substanzen

Fibrinolytic Agents

Autor:innen und Institutionen

  • Ochsner LSU Health Shreveport-Academic Medical Center, Shreveport, LA, USA.
  • The University of Tennessee Medical Center, Knoxville, TN, USA.
  • Ochsner LSU Health Shreveport-Academic Medical Center, Shreveport, LA.
  • University of Louisiana at Monroe College of Pharmacy, Monroe, LA, USA.

Zitieren

APA

Robichaux, T., Edwards, K., Carter, A., Washington, A., & Brooks, S. (2024). Analysis of appropriateness and safety when discharging patients on triple-antithrombotic therapies. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae068

Vancouver

Robichaux T, Edwards K, Carter A, Washington A, Brooks S. Analysis of appropriateness and safety when discharging patients on triple-antithrombotic therapies. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae068

BibTeX
@article{Robichaux2024,
  author = {Robichaux, Taylor and Edwards, Kristyn and Carter, Ashley and Washington, Andrea and Brooks, Shelby},
  title = {Analysis of appropriateness and safety when discharging patients on triple-antithrombotic therapies},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae068}
}
Kostenlos starten →